SCHEMBL6853790

SCHEMBL6853790

Cc1cc(CC(=O)O)cc(C)c1Oc1ccc2[nH]cc(CC(C)C)c2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRA P10827 5/20 0.55
THRB P10828 5/20 0.55
KDM4E B2RXH2 2/20 0.53
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
HSP90AA1 P07900 1/20 0.47
HSP90AB1 P08238 1/20 0.47
LTA4H P09960 1/20 0.47
PLA2G2A P14555 1/20 0.47
TRPV1 Q8NER1 1/20 0.45
PPARG P37231 1/20 0.45
PPARD Q03181 1/20 0.45
PPARA Q07869 1/20 0.45
HTR1A P08908 2/20 0.45
HTR2A P28223 2/20 0.45
HTR2C P28335 2/20 0.45
HTR2B P41595 2/20 0.45
SCN9A Q15858 2/20 0.43
TSHR P16473 3/20 0.43
ALDH1A1 P00352 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6514451 0.93 THRA (0.51) THRATHRBKDM4EKMT2AMEN1
SCHEMBL6512855 0.93 THRB (0.51) THRATHRBKDM4EKMT2AMEN1
SCHEMBL6511148 0.91 THRA (0.68) THRATHRBKDM4EKMT2AMEN1
SCHEMBL6514219 0.88 THRA (0.54) THRATHRBKDM4EKMT2AMEN1
SCHEMBL6516973 0.88 THRA (0.54) THRATHRBKDM4ETRPV1
SCHEMBL6510961 0.88 THRB (0.54) THRATHRBKDM4EKMT2AMEN1
SCHEMBL6516537 0.86 KDM4E (0.54) THRATHRBKDM4EKMT2ALTA4H
SCHEMBL6510913 0.86 THRA (0.75) THRATHRBKDM4EKMT2AMEN1
SCHEMBL6517117 0.85 KDM4E (0.53) THRATHRBKDM4EKMT2AMEN1
SCHEMBL6521709 0.85 THRA (0.74) THRATHRBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6794406-B2 FOR THERAPY AND PROPHYLAXIS OF ARTERIOSCLEROSIS AND HYPERCHOLESTEROLAEMIA BAYER AKTIENGESELLSCHAFT (DE) 2004-09-21 US disclosed
EP-1347959-A1 INDOLE DERIVATIVES AS LIGANDS OF THYROID RECEPTORS Bayer Aktiengesellschaft (DE) 2003-10-01 EP disclosed
US-20030078288-A1 Indole derivatives BAYER AKTIENGESELLSCHAFT (DE) 2003-04-24 US disclosed
WO-2002051805-A1 INDOLE DERIVATIVES AS LIGANDS OF THYROID RECEPTORS BAYER AKTIENGESELLSCHAFT (DE) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078288-A1 Indole derivatives IDO1, IDO2, TPH2 THRA 2460/4885THRB 1772/4885KDM4E 1199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.